The 2026 pharmaceutical industry outlook is shaped by regulatory volatility, innovation funding cuts, and protectionist trade tariffs. Key priorities include infusing AI across R&D, reshaping portfolios toward high-value assets, and fortifying supply chains through regional manufacturing.